Nachweis der BRAF-V600E-Mutation beim metastasierten kolorektalen Karzinom

[1]  K. Bencardino,et al.  The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer , 2021, Cancers.

[2]  Harpreet Wasan,et al.  Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. , 2019, The New England journal of medicine.

[3]  C. Has,et al.  Dermatologische Diagnostik: Suche nach dem molekularen „Fingerabdruck“ , 2018 .

[4]  W. Oyen,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Sabine Tejpar,et al.  BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression , 2016, Clinical Cancer Research.

[6]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[7]  E. Oikonomou,et al.  BRAFV600E Efficient Transformation and Induction of Microsatellite Instability Versus KRASG12V Induction of Senescence Markers in Human Colon Cancer Cells , 2009 .

[8]  W. Hiddemann,et al.  The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status. , 2009, Deutsches Arzteblatt international.

[9]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[10]  E. Oikonomou,et al.  BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. , 2009, Neoplasia.